A phase I study to assess the safety, tolerability, and PK of ARRY-380, an oral HER2

[Hopeful]

inhibitor

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60567

Hopeful